Pubblicazioni Scientifiche Anno 2011 - Azienda Ospedaliera Santi ...

protocol: italian study on over 100 patients” - EHA – Londra 9-12 giugno2011, Haematologica 2011; 96: 23927. Luminari S., Versari A., Quaresima M., Arcaini L., Rusconi C., GallaminiA., Zinzani P.L., Franceschetti S., Boccomini C., JM Ferreri A., Spina M.,D'Arco A., Di Raimondo F., Carella A.M., Balzarotti M., Aversa S., CalleaV., Musto P., Pinotti G., Freilone R., Centurioni R., Morabito F.,Bertoldero G., Levis A., Rigacci L., Tedeschi L., Pulsioni A. and FedericoM. “Role of FDG-PET as prognostic indicator in patients with FollicularLymphoma(FL) after immunochemotherapy induction. A retrospectivestudy from the Fondazione Italiana Linfomi” - ASH – San Diego,California 10-13 dicembre 2011, sessione poster28. Merli M., Spina M., Luminari S., Stelitano C., Ferretti V., Gabutti C.,Targhetta C., Visco C., Levis A., Rossi D., D’Arco A.M., Rigacci L.,Ambrosetti A., Chiappella A., Musto P., Arcaini L. “Prognostic models foroutcome prediction in Non-Hodgkin’s lymphomas associated with hepatitisC virus infection: a multicenter study of 1.123 patients on behalf of theFondazione Italiana Linfomi (FIL)” - 11 th International Conference onMalignant Lymphoma – Lugano 18-21 giugno 2011, Annals of Oncology2011; 22 (suppl. 4)29. Santini V., Sanna A., Bosi A., Alimena G., Loglisci G., Levis A., Salvi F.,Finelli C., Clissa C., Specchia G., Ricco A., Cortelezzi A., Ferla V.,Sciumé M., Nobile F., Oliva E., Lazzaro C., Econ D. and Martelli E. “Anobservational multicenter study to assess the cost of illness and quality oflife in patients with myelodysplastic syndromes in Italy” - ASH – SanDiego, California 10-13 dicembre 2011, comunicazione orale30. Spina M., Antinori A., Bibas M., Re A., Mancuso S., Levis A., TalaminiR., Tirelli U. “Vebep regimen in patients (Pts) with Hd and Hiv Infection(Hd-Hiv): final results of a phase II study of the Italian Cooperative Groupon Aids and Tumors (GICAT)” - EHA – Londra 9-12 giugno 2011,Haematologica 2011; 96: 32031. Spina M., Antinori A., Bibas M., Re A., Mancuso S., Levis A., TalaminiR., Tirelli U. “Vebep regimen and Highly Active Antiretroviral Therapy(HAART) in patients (PTS) with HD and HIV Infection (HD-HIV): finalresults of a phase II study of the Italian Cooperative Group on Aids andTumors (GICAT) study” - 11 th International Conference on MalignantLymphoma – Lugano 18-21 giugno 2011, Annals of Oncology 2011; 22(suppl. 4)32. Vitolo U., Chiappella A., Carella A.M., Baldi L., Botto B., Ciccone G.,Congiu A., Gaidano G., De Masi P., Ladetto M., Levis A., Liberati A.M.,Pavone V., Perticone S., Tucci A., Rossi G. “Lenalidomide plus rituximab-Chop21 in elderly untreated Diffuse Large B-Cell Lymphoma (DLBCL):results of phase I part of Real07 trial of Italian Lymphoma Foundation(FIL)” - 11 th International Conference on Malignant Lymphoma – Lugano18-21 giugno 2011, Annals of Oncology 2011; 22 (suppl. 4)33. Vitolo U., Chiappella A., Carella A., Baldi I., Botto B., Ciccone G., CongiuA., Gaidano G., De Masi P., Ladetto M., Levis A., Liberati A.M., PavoneV., Perticone S., Tucci A., Zanni M., Rossi G. “Lenalidomide plusrituximab-chop21 is safe and effective in elderly untreated diffuse large B-cell lymphoma (Dlbcl): results of phase I part of Real07 trial of ItalianLymphoma Foundation (FIl)” - EHA – Londra 9-12 giugno 2011,Haematologica 2011; 96: 154-15534. Voso M.T., Fianchi L., Criscuolo M., Levis A., Finelli C., Musto P.,Maurillo L., Oliva E.N., Greco M., Pagano L., Leone G. “Response to 5-Azacytidine in Therapy-Related Malignant Neoplasms (T-MN)” - MDSEdinburgo 18-21 maggio 2011, Leukemia Research 2011; 35: 57635. Chiappella A., Castellino A., Cabras M.G., Liberati A.M., Evangelista A.,Battelli C., Salvi F., Rossi A., Pavone V., Nicolosi M., Parvis G., Tonso A.,Rossigni F., Pecoraio C., Rota-Scalabrini D., Luminari S., De Masi P.,Perticone S., Cascavilla N., Freilone R. and Vitolo U. “Prolonged survivalwith low incidence of CNS relapse and late toxicities in a retrospectiveseries of 278 young patients with high-risk (aa-IPI 2–3) diffuse large B-Cell lymphoma treated with intensified chemotherapy with or without15